Development Areas 2015-2022
Personalised Medicine Development Area
Personalised Medicine Development Area (DA) is focused on eliminating several bottlenecks that globally hinder the application of the achievements of molecular medicine and info- and communication technology (ICT) in the interests of human health. Therefore, we have set the general aims of personalised medicine DA as combining the recent key advances in medical and population genetics, bioinformatics, E-Health and ICT in general, to develop preventive, diagnostic and treatment algorithms and decision-support systems for personalised medicine for common complex diseases and cancer.
Projects in this Development Area (DA) are predominantly focused on novel cancer treatment drugs and delivery systems, as well as production technologies for diagnostically and therapeutically useful recombinant peptides and proteins. In this DA, we are also continuing our previous work on the bovine transgenic cloning technologies that have brought us considerable international attention, as we witnessed the birth of transgenic cows with human genes for insulin and follicle-stimulating hormone, in 2013 and 2014, respectively. However, these technologies are still hampered by several technological limitations – particularly by the poor health and rates of survival of the transgenic cloned animals. Tackling the technological challenges will enable business application of CCHT research results in the pharmaceutical industry.
Reproductive Medicine Development Area (DA) projects will contribute to solving some of the most pressing issues in contemporary reproductive and fetal medicine. In this DA, we create diagnostic systems for female reproductive diseases as well as develop new solutions for identifying fetal genetic diseases by non-invasive prenatal testing (NIPT). In this DA, we also continue with the development of clinically proven probiotic strains for female and male reproductive disorders. In the era of increased use of antibiotics in human medicine, there has also been an increase in the incidence of antibiotic-associated complications caused by increased bacterial resistance. Therefore, we continue with our plans for studying those probiotic strains that are helpful in the biological treatment of infectious diseases of the reproductive tract. CCHT also continues with developint veterinary reproductive technologies, with the aim to validate novel biomarkers for sperm sex-sorting and fertility evaluation of cattle, a task that is technologically challenging but at the same time carries a high business potential.